全文获取类型
收费全文 | 19481篇 |
免费 | 1737篇 |
国内免费 | 1664篇 |
专业分类
耳鼻咽喉 | 659篇 |
儿科学 | 59篇 |
妇产科学 | 270篇 |
基础医学 | 1300篇 |
口腔科学 | 360篇 |
临床医学 | 1694篇 |
内科学 | 4477篇 |
皮肤病学 | 218篇 |
神经病学 | 30篇 |
特种医学 | 1201篇 |
外科学 | 4483篇 |
综合类 | 2480篇 |
预防医学 | 471篇 |
眼科学 | 37篇 |
药学 | 845篇 |
1篇 | |
中国医学 | 127篇 |
肿瘤学 | 4170篇 |
出版年
2024年 | 13篇 |
2023年 | 220篇 |
2022年 | 603篇 |
2021年 | 776篇 |
2020年 | 623篇 |
2019年 | 499篇 |
2018年 | 541篇 |
2017年 | 490篇 |
2016年 | 696篇 |
2015年 | 883篇 |
2014年 | 1273篇 |
2013年 | 1123篇 |
2012年 | 1257篇 |
2011年 | 1334篇 |
2010年 | 1147篇 |
2009年 | 1132篇 |
2008年 | 1122篇 |
2007年 | 1187篇 |
2006年 | 1169篇 |
2005年 | 1085篇 |
2004年 | 778篇 |
2003年 | 734篇 |
2002年 | 615篇 |
2001年 | 649篇 |
2000年 | 531篇 |
1999年 | 460篇 |
1998年 | 303篇 |
1997年 | 313篇 |
1996年 | 245篇 |
1995年 | 209篇 |
1994年 | 166篇 |
1993年 | 106篇 |
1992年 | 64篇 |
1991年 | 48篇 |
1990年 | 59篇 |
1989年 | 46篇 |
1988年 | 54篇 |
1987年 | 35篇 |
1986年 | 31篇 |
1985年 | 46篇 |
1984年 | 29篇 |
1983年 | 26篇 |
1982年 | 31篇 |
1981年 | 30篇 |
1980年 | 36篇 |
1979年 | 28篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1972年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
《European journal of surgical oncology》2022,48(3):621-631
ObjectivesThe aim of this meta-analysis was to conduct a contemporary systematic review of high quality non-randomised controlled trials to determine the effect of pre-liver transplantation (LT) transarterial chemoembolisation (TACE) on long-term survival and complications of hepatocellular carcinoma (HCC) patients.BackgroundTACE is used as a neoadjuvant therapy to mitigate waitlist drop-out for patients with HCC awaiting LT. Previous studies have conflicting conclusions on the effect of TACE on long-term survival and complications of HCC patients undergoing LT.MethodsCINAHL, Cochrane Controlled Register of Trials, Embase, PubMed, and Web of Science were systematically searched. Baseline characteristics included number of patients outside Milan criteria, tumour diameter, MELD score, and time on the waiting list. Primary outcomes included 3- and 5-year overall and disease-free survival. Secondary outcomes included tumour recurrence, 30-day postoperative mortality, and hepatic artery and biliary complications.ResultsTwenty-one high-quality NRCTs representing 8242 patients were included. Tumour diameter was significantly larger in TACE patients (3.49 cm vs 3.15 cm, P = 0.02) and time on the waiting list was significantly longer in TACE patients (4.87 months vs 3.46 months, P = 0.05), while MELD score was significantly higher in non-TACE patients (10.81 vs 12.35, P = 0.005). All primary and secondary outcomes displayed non-significant differences.ConclusionPatients treated with TACE had similar survival and postoperative outcomes to non-TACE patients, however, they had worse prognostic features compared to non-TACE patients. These findings strongly support the current US and European clinical practice guidelines that neoadjuvant TACE can be used for patients with longer expected waiting list times (specifically >6 months). Randomised controlled trials would be needed to increase the quality of evidence. 相似文献
2.
Xiao-Long Tang Yan-Dong Miao Deng-Hai Mi 《World journal of gastrointestinal oncology》2022,14(1):366-368
The present letter to the editor is in response to the research “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis” by Elshaarawy et al in World J Gastroenterol 2021; 13(5): 424–439. The preoperative assessment of the liver reserve function in hepatocellular carcinoma (HCC) patients with cirrhosis is crucial, and there is no universal consensus on how to assess it. Based on a retrospective study, Elshaarawy et al investigated the impact of various classical clinical indicators on liver failure and the prognosis after hepatectomy in HCC patients with cirrhosis. We recommend that we should strive to explore new appraisal indicators, such as the indocyanine green retention rate at 15 min. 相似文献
3.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
4.
Wang-Shu Zhu Si-Ya Shi Ze-Hong Yang Chao Song Jun Shen 《World journal of gastroenterology : WJG》2020,26(11):1208-1220
BACKGROUND Postoperative liver failure is the most severe complication in cirrhotic patients with hepatocellular carcinoma(HCC) after major hepatectomy. Current available clinical indexes predicting postoperative residual liver function are not sufficiently accurate.AIM To determine a radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting liver failure in cirrhotic patients with HCC after major hepatectomy.METHODS For this retrospective study, a radiomics-based model was developed based on preoperative hepatobiliary phase gadoxetic acid-enhanced magnetic resonance images in 101 patients with HCC between June 2012 and June 2018. Sixty-one radiomic features were extracted from hepatobiliary phase images and selected by the least absolute shrinkage and selection operator method to construct a radiomics signature. A clinical prediction model, and radiomics-based model incorporating significant clinical indexes and radiomics signature were built using multivariable logistic regression analysis. The integrated radiomics-based model was presented as a radiomics nomogram. The performances of clinical prediction model, radiomics signature, and radiomics-based model for predicting post-operative liver failure were determined using receiver operating characteristics curve, calibration curve, and decision curve analyses.RESULTS Five radiomics features from hepatobiliary phase images were selected to construct the radiomics signature. The clinical prediction model, radiomics signature, and radiomics-based model incorporating indocyanine green clearance rate at 15 min and radiomics signature showed favorable performance for predicting postoperative liver failure(area under the curve: 0.809-0.894). The radiomics-based model achieved the highest performance for predicting liver failure(area under the curve: 0.894; 95%CI: 0.823-0.964). The integrated discrimination improvement analysis showed a significant improvement in the accuracy of liver failure prediction when radiomics signature was added to the clinical prediction model(integrated discrimination improvement = 0.117, P =0.002). The calibration curve and an insignificant Hosmer-Lemeshow test statistic(P = 0.841) demonstrated good calibration of the radiomics-based model. The decision curve analysis showed that patients would benefit more from a radiomics-based prediction model than from a clinical prediction model and radiomics signature alone.CONCLUSION A radiomics-based model of preoperative gadoxetic acid–enhanced MRI can be used to predict liver failure in cirrhotic patients with HCC after major hepatectomy. 相似文献
5.
Jingjing He Lingyi Zhang Dan Guo Xingwen Han Hui Zhang Liang Wang Youcheng
Zhang 《Oncologie》2020,22(1):1-12
Hepatocellular carcinoma (HCC) ranks the sixth place of most common
cancers. Meanwhile, it is the tertiary mortality cause of cancer. There is no
effective therapeutic method to prevent and treat the liver cancer. Sinomenine is a
kind of Chinese traditional medicine herbal, it is reported that it can inhibit the
viability of several cancer cells. The study is to explore whether sinomenine is also
able to inhibit the cell viability of HCC and its potential mechanism. The IC50 of
sinomenine in BEL-7402 cells was 5.351 mmol/L, and the IC50 of sinomenine in
SMMC-7721 cells was 6.204 mmol/L. The gene expression results showed the
relative expression of FGF2, CCND2, DCN, F3, MMP7, NRG1, HMGB1,
TRIM29, HAS2, EHF, CTGF, PLK2 were down-regulated, and the relative
expression of VEGF A, CITED2, NUPR1, DDX58, IRF9, NAMPT, MMP1,
NDRG1, HMGA2, PPARGC1A, IFIT2, PARP9, HEY1, LOX, ETV1, ISG15,
BACH, CYLD were up-regulated. Moreover, the IPA analysis results suggested
that IFIT3, IFIT1, OAS1, MX1, IRF9, IFI6, IFITM1, ISG15 were up-regulated in
BEL-7402 cells treated with sinomenine by activating IFNA2. The findings
presented in this study may provide a promising method for the prevention and
treatment of liver cancer. 相似文献
6.
《中国现代医生》2020,58(29):24-27+封三
目的 探讨肝癌组织中LncRNA TINCR 表达水平对术后长期生存的影响。方法 回顾性分析2013 年4 月~2016 年2 月间在本院接受手术治疗的157 例肝细胞肝癌患者的临床资料。RT-PCR 法检测肝癌标本内LncRNA TINCR 表达水平,采用ROC 曲线和Kaplan-Meier 法分析LncRNA TINCR 表达水平对肝癌术后长期生存的影响。结果 肝癌组织LncRNA TINCR 表达水平对术后长期生存预测的曲线下面积(AUC)为0.812,特异度为73.77%,灵敏度为79.17%,最佳判读值为1.89(P<0.0001)。根据ROC 曲线分析结果,将肝癌组织LncRNA TINCR 相对表达水平大于1.89 的93 例(59.24%)患者纳入高表达组,而肝癌组织LncRNA TINCR 相对表达水平小于或等于1.89的64 例(40.76%)患者纳入低表达组。Kaplan-Meier 法生存分析发现高表达组术后3 年内有76 例患者死亡,3 年总生存率为18.28%(17/93);低表达组术后3 年内有20 例患者死亡,3 年总生存率为68.75%(44/64),低表达组3 年总生存率明显优于高表达组(P<0.0001,两组间死亡风险比为3.7534,95%可信区间为2.5158~5.6000)。结论 肝癌组织LncRNA TINCR 表达水平与肝癌术后长期生存显著相关,LncRNA TINCR 表达水平升高则预示着预后不佳。 相似文献
7.
《Anais brasileiros de dermatologia》2019,94(1):42-46
BackgroundSkin cancer is a highly prevalent condition with a multifactorial etiology resulting from genetic alterations, environmental and lifestyle factors. In Brazil, among all malignant tumors, skin cancers have the highest incidences.ObjectiveTo retrospectively evaluate the incidence, prevalence and profile of basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma in Campos dos Goytacazes and region.Methods:In total, 2,207 histopathological reports of a local reference hospital were analyzed between January 2013 and December 2015, of which 306 corresponded to the neoplasms studied.Results:Of the 306 reports evaluated, 232 basal cell carcinomas (75.9%), 55 squamous cell carcinomas (18%) and 19 cutaneous melanomas (6.5%) were identified. The face was the most involved anatomical site (58.8%) and women (51%) were the most affected gender. The temporal analysis revealed a decrease in the overall incidence of 3.4% from 2013 to 2014 and 5.4% from 2014 to 2015. There was a 10.1% increase in basal cell carcinomas and 38% in melanomas in this period; however, there was a decrease in the number of squamous cell carcinomas of 14.8% during the studied years.Study limitations:Some samples of cutaneous fragments had no identification of the anatomical site of origin.Conclusion:Research that generates statistical data on cutaneous tumors produces epidemiological tools useful in the identification of risk groups and allows the adoption of more targeted and efficient future prevention measures. 相似文献
8.
目的以基因表达数据集资料为研究对象,分析BCAN基因在肾透明细胞癌中的表达情况以及对患者预后的影响。方法在Oncomine数据库中挖掘BCAN在肾透明细胞癌(ccRCC)中的表达情况。从TCGA数据库中获取ccRCC患者临床资料和目的基因的表达信息并进行统计分析。利用GEO数据库中GSE73731数据集的ccRCC样本进行基因富集分析。利用String数据库分析与BCAN相关的蛋白。结果BCAN低表达组的ccRCC患者在病理分期及T分期方面低于高表达组(P<0.001;P=0.001);N分期及M分期差异无统计学意义(P>0.05)。BCAN低表达组患者的总生存期优于高表达组(P=0.033)。BCAN基因高表达组的样本主要富集在KRAS信号通路。结论BCAN可以通过多种途径来促进肿瘤细胞的侵袭能力,有望成为ccRCC不良预后的重要生物标志物之一。 相似文献
9.
10.
Hui-Ju Ch’ang 《World journal of hepatology》2015,7(16):2029-2040
The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To enhance therapeutic efficacy, overcome drug resistance and reduce toxicity, combination of antiangiogenic agents with chemotherapy, radiotherapy or other targeted agents were evaluated. Nevertheless, the use of antiangiogenic therapy remains suboptimal regarding dosage, schedule and duration of therapy. The issue is further complicated by combination antiangiogenesis to other cytotoxic or biologic agents. There is no way to determine which patients are most likely respond to a given form of antiangiogenic therapy. Activation of alternative pathways associated with disease progression in patients undergoing antiangiogenic therapy has also been recognized. There is increasing importance in identifying, validating and standardizing potential response biomarkers for antiangiogenesis therapy for HCC patients. In this review, biomarkers for antiangiogenesis therapy including systemic, circulating, tissue and imaging ones are summarized. The strength and deficit of circulating and imaging biomarkers were further demonstrated by a series of studies in HCC patients receiving radiotherapy with or without thalidomide. 相似文献